New Jersey Telemedicine Laws: License, Prescribing, Consent

New Jersey pairs an easy front door with some of the strictest prescribing rails on the East Coast. Getting licensed is straightforward — the state is an Interstate Medical Licensure Compact member — but once you're treating New Jersey patients, you'll deal with a signed acknowledgment of telehealth notice, a mandatory PMP look-up regime, its own controlled substance registration, and a Schedule II rule that's tougher than federal law. Payment parity, meanwhile, was just extended through the end of 2027.

Licensure: NJ license required, compact available

Under the state's Telemedicine Act (N.J.S.A. 45:1-62), any provider using telemedicine with a patient located in New Jersey must be licensed here and answers to the New Jersey board — and jurisdiction attaches if either the patient or the provider is in the state. There's no separate telehealth registration; the license is the pathway.

The practical difference from a state like New York is the compact. New Jersey joined the IMLC in 2022, so a physician with a clean license elsewhere can use the expedited process rather than a from-scratch application. The state also belongs to the nursing, psychology (PSYPACT), physical therapy, and social work compacts, and, since January 2026, the physician assistant compact. It has joined the Counseling Compact as well, though privileges are not yet being issued there.

The licensure exception is narrow: an out-of-state provider who consults with a New Jersey licensee through technology, but does not direct patient care, does not need a New Jersey license for that consultation (N.J.A.C. 13:35-6B.1(d)). A separate rule lets New Jersey licensees skip the usual relationship-forming steps for informal, uncompensated consultations with another provider; episodic consultations requested from an out-of-state specialist; emergency or disaster assistance provided free of charge; and on-call or cross-coverage by a substitute for an absent licensee in the same specialty (N.J.A.C. 13:35-6B.4(c)). Those are exceptions to the relationship requirement, not to licensure. What New Jersey notably does not have is a follow-up-care exception for established patients who happen to be in the state — if your patient is physically in New Jersey, treat the licensure requirement as applying.

Prescribing: the Schedule II rule is the headline

The telemedicine relationship itself can be formed remotely — real-time audio-video (or store-and-forward where the standard of care supports it), with a review of the patient's history and records before the first encounter, disclosure of the provider's identity and credentials, and availability for follow-up for at least 72 hours after the visit.

Controlled substances are where New Jersey diverges from the federal baseline. As the default, state law requires an initial in-person examination, plus in-person visits every three months, for Schedule II substances prescribed via telemedicine (N.J.S.A. 45:1-62(e)). That's stricter than the federal rule — and state law wins for New Jersey patients. P.L.2026, c.40, approved July 8, 2026 and effective immediately, rewrote the exceptions:

• Minors' stimulants. A Schedule II stimulant for a patient under 18 may be prescribed without the in-person exam if a parent or guardian first gives written consent waiving it.
• Exempt patients and drugs. The in-person rule does not apply to patients in active cancer treatment, receiving hospice or palliative care, or living in a long-term care facility; to patients being evaluated or treated under the Medical Aid in Dying for the Terminally Ill Act; or to medications prescribed to treat a substance use disorder.
• Adult stimulants. For an adult, the initial examination before a Schedule II stimulant may be in person or by telehealth. If it is by telehealth, an in-person visit is required within 30 days; after that, the prescriber must have an in-person or telehealth contact every three months and an in-person visit at least once a year.
• Video required. Any Schedule II prescription through telemedicine or telehealth requires real-time two-way audio and video.

Anyone running an ADHD-adjacent telepsychiatry practice should design adult workflows around the 30-day, three-month, and annual cadence rather than hoping federal rules preempt it — they don't.

Other state duties apply to telehealth exactly as in person:

• State registration. New Jersey requires its own controlled dangerous substance (CDS) registration, issued by the Division of Consumer Affairs' Drug Control Unit, for every person who prescribes CDS within the state; it is issued to an actual location where CDS will be stored, prescribed, or dispensed, and it is the prerequisite to a DEA registration. Out-of-state telehealth prescribers should confirm with the Drug Control Unit how the location requirement applies to them.
• PMP. A practitioner must register for NJPMP access when applying for or renewing the CDS registration (N.J.S.A. 45:1-46(h)(1)). The practitioner or an authorized delegate must check the NJPMP the first time the practitioner prescribes a Schedule II controlled substance or any opioid to a new patient for acute or chronic pain, the first time the practitioner prescribes a Schedule III or IV benzodiazepine, and the first time the practitioner prescribes another Schedule III or IV non-opioid drug when the practitioner reasonably believes the patient may be seeking it for misuse, abuse, or diversion. The check must be repeated at least quarterly while a new patient continues on a Schedule II drug or opioid for pain, or on a Schedule III or IV benzodiazepine. The statute lists exceptions, including hospice patients, drugs administered directly, certain emergency department and post-surgical supplies of five days or less, and system outages (N.J.S.A. 45:1-46.1).
• Opioid limits. An initial opioid prescription for acute pain may not exceed a five-day supply, at the lowest effective dose of an immediate-release opioid. Before the first Schedule II or opioid prescription for acute or chronic pain, the practitioner must take and document a history, examine the patient as appropriate, develop a treatment plan, and check the NJPMP. The practitioner must discuss the risks with the patient, or with the parent or guardian of an unemancipated minor, before the initial acute-pain prescription and at the outset of chronic-pain treatment, and must enter into a pain management agreement before starting an ongoing course of chronic-pain treatment with a Schedule II drug or any opioid. The limits do not apply to patients in active cancer treatment, hospice or palliative care, or long-term care, or to medications for substance use disorder (N.J.S.A. 24:21-15.2, as amended by P.L.2017, c.341).
• E-prescribing. We found no New Jersey statute requiring electronic prescribing; the Board of Medical Examiners rule permits it without mandating it (N.J.A.C. 13:35-7.4A). Medicare Part D separately requires at least 70 percent of Part D Schedule II–V prescriptions to be electronic under 42 CFR 423.160, subject to exceptions and waivers.

Federal law adds a separate layer for controlled substances. Under the temporary rule DEA and HHS published December 31, 2025 (90 FR 61301), which runs through December 31, 2026, a DEA-registered practitioner may prescribe Schedule II–V controlled substances after a real-time audio-video telemedicine encounter without a prior in-person evaluation, when the rule's other conditions are met; audio-only encounters qualify only for Schedule III–V narcotic medications approved by the FDA to treat opioid use disorder. New Jersey's Schedule II rule applies on top of that federal rule. Our report on the DEA telemedicine prescribing extension covers the federal layer.

Consent and the signed notice acknowledgment

New Jersey adds a notice step for physicians. The Telemedicine Act allows consent to be oral, written, or digital, provided the method is appropriate under the standard of care (N.J.S.A. 45:1-62(c)(5)). The Board of Medical Examiners rule adds a paperwork step: before telehealth services, the licensee must give the patient notice covering the risks and benefits of telemedicine or telehealth and how to obtain follow-up care or help after an adverse reaction or a technology failure, and must obtain a signed and dated statement that the patient received the notice (N.J.A.C. 13:35-6B.9(e)). Build that signed acknowledgment into intake; a verbal yes can be valid consent, but it does not replace the acknowledgment the Board requires.

Medicaid: NJ FamilyCare covers broadly, including audio-only

NJ FamilyCare covers live video, store-and-forward, remote patient monitoring — and audio-only, which the statute protects explicitly by barring restrictions on the electronic platform used. There are no originating-site restrictions; the patient's home is valid (billed with place-of-service 10).

Payment runs at parity with in-person rates, with one calibrated exception: audio-only behavioral health is paid at full parity, while audio-only physical health services must be paid at no less than half the in-person rate. The parity requirement currently runs through December 31, 2027.

That parity is what makes NJ FamilyCare a realistic route to behavioral health care rather than a nominal one. Patients asking what it covers in practice — copays, referrals, which levels of care qualify — can start with PsychMentalHealth's plain-language breakdown of NJ FamilyCare mental health coverage. (Disclosure: PsychMentalHealth is affiliated with ZSKFL Management, which owns TeleMed Today.)

Private insurance: coverage permanent, payment through 2027

Coverage parity is permanent — carriers must cover telehealth-delivered services on the same basis as in-person, and cost sharing cannot exceed the in-person amount, but a carrier may limit that coverage to providers in the plan's network (N.J.S.A. 26:2S-29). Carriers may not restrict the originating or distant site, may not restrict the platform a provider uses, including audio-only telephone, if it meets the standard of care and HIPAA, and may not limit coverage to select third-party telehealth companies. The statute sets no telehealth-specific utilization review rule; it lets carriers cover only medically necessary services, subject to the plan's terms and conditions. Payment parity has lived on extensions since 2021; the latest, signed June 30, 2026, carries it through December 31, 2027. Same audio-only nuance as Medicaid: rate parity for behavioral health, not for physical-health audio-only. One quirk worth knowing: parity doesn't extend to telemedicine-only organizations that don't also deliver in-person care in New Jersey. The broader payer picture is in our telehealth reimbursement guide.

What to watch

The December 2027 parity sunset is the next legislative moment, and the DEA's pending special-registration rulemaking will determine how much friction the Schedule II regime creates in practice. If the federal flexibilities lapse without a replacement, New Jersey's in-person requirements simply become the national default again — which is exactly why practices here that built hybrid workflows haven't had to scramble with each extension cycle. For how New Jersey compares to New York and Pennsylvania, start with the national overview.